Interpace Diagnostics to Present at the Dawson Jam

PARSIPPANY, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) today announced that Jack Stover, the Company’s President and CEO is scheduled to present on Thursday October 19 ^th at 11:30 am ET at the Dawson James Securities 3 ^rd Annual Small Cap Growth Conference at the Wyndham Grand Jupiter at Harbourside Place, Jupiter, Florida. One-on-one meetings will be held throughout the conference.

About Interpace Diagnostics Group, Inc. Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has four commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and MVPdX that helps differentiates the local recurrence of lung cancer versus new primary cancer formation. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information please visit the Company’s website at www.interpacediagnostics.com . 

CONTACTS:

Interpace Diagnostics Investor Relations: Paul Kuntz – Redchip paul@redchip.com